Clinical Trial Details

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

IRB Protocol Number

NRG GI004

Clinical Trial Categories

• Colorectal Cancer

Contact

Clinical Trials at 910-715-2200

How to Participate

Eligibility: Men or women, ages 18 and older, diagnosed with Deficient DNA Mismatch repair metastatic colorectal cancer